



COVID-19 Vaccine Related Codes

COVID-19 Vaccine Codes

Preview Posting of COVID-19 Vaccine Codes and Crosswalk for Currently Authorized Vaccines and Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)

Note: Codes will become effective only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)

The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization.

The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.

To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.

The codes for these vaccines are also included in the vaccine code set files unless otherwise noted in the table. Additional code details and fields values are included in the vaccine code sets.

American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site. The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets. You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:

<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>

Download the Preview Table *for US vaccine administration only*. [Excel Version](#)

COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA) as of 02/14/2022. Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA

Manufacturer	FDA Authorization (BLA, EUA, Pre-EUA)	Sale Proprietary Name	Product Description	Unit of Sale NDC10 (UOS)	UoS Package	Unit of Use NDC10 (UOU)	UoU Presentation	CVX Code	CVX Long Description	CVX SI Descri
Janssen Products, LP	EUA-authorized (18+)	Janssen COVID-19 Vaccine (BLUE CAP)	5×10 ¹⁰ viral particles/0.5 mL for adult 18+	59676-580-15	CARTON, 10 MULTI-DOSE VIALS	59676-580-05	VIAL, MULTI-DOSE	212	SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL	COVID vector PF, 0,5
Moderna US, Inc.	EUA-authorized (18+)	Moderna COVID-19 Vaccine (RED CAP)	100 mcg/0.5 mL for adult 18+ (existing product)	80777-273-99	CARTON, 10 MULTI-DOSE VIAL 5 mL EACH	80777-273-10	VIAL, 5 mL, MULTI-DOSE VIAL	207	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	COVID LNP-S, mcg/0 50 mcg
				80777-273-98	CARTON, 10 MULTI-DOSE VIAL 7 mL EACH	80777-273-15	VIAL, 7 mL, MULTI-DOSE VIAL			
Moderna US, Inc.	EUA-authorized (18+)	Moderna COVID-19 Vaccine (RED CAP)	50 mcg/0.25 mL for booster adult 18+ (existing product), drawn from same vial as primary series	80777-273-99	CARTON, 10 MULTI-DOSE VIAL 5 mL EACH	80777-273-10	VIAL, 5 mL, MULTI-DOSE VIAL	207	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	COVID LNP-S, mcg/0 50 mcg
				80777-273-98	CARTON, 10 MULTI-DOSE VIAL 7	80777-273-15	VIAL, 7 mL, MULTI-DOSE VIAL			

Manufacturer	FDA Authorization (BLA, EUA, Pre-EUA)	Sale Proprietary Name	Product Description	Unit of Sale NDC10 (UOS)	UoS Package	Unit of Use NDC10 (UOU)	UoU Presentation	CVX Code	CVX Long Description	CVX SI Descri
Pfizer-BioNTech	EUA-authorized for ages 12 yrs +	Pfizer-BioNTech COVID-19 Vaccine (PURPLE CAP) (Original product formulation)	30 mcg/0.3 mL for primary series, IC 3rd dose, booster	59267-1000-2	CARTON, 195 MULTI-DOSE VIALS	59267-1000-1	MULTI-DOSE VIAL	208	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose	COVID LNP-S, mcg/0
				59267-1000-3	CARTON, 25 MULTI-DOSE VIALS					
Pfizer-BioNTech	EUA-authorized for ages 12 yrs + Note: BLA-licensed for (16+)	Pfizer-BioNTech COVID-19 Vaccine (GRAY CAP) (Tris-sucrose formulation)	30 mcg/0.3 mL for primary series, IC 3rd dose, booster	59267-1025-3	CARTON, 25 MULTI-DOSE VIALS	59267-1025-1	VIAL, 2.25 mL, MULTI-DOSE VIAL	217	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose	COVID LNP-S, mcg/0
				59267-1025-4	CARTON, 10 MULTI-DOSE VIALS					
Pfizer-BioNTech	EUA-authorized for ages 5 yrs to < 12 yrs	Pfizer-BioNTech COVID-19 Vaccine (ORANGE CAP) (Tris-sucrose formulation)	10 mcg/0.2 mL for primary series, IC 3rd dose	59267-1055-4	CARTON, 10 MULTI-DOSE VIALS	59267-1055-1	VIAL, 2 mL, MULTI-DOSE VIAL	218	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation	COVID LNP-S, mcg/0 tris-su


Manufacturer	FDA Authorization (BLA, EUA, Pre-EUA)	Sale Proprietary Name	Product Description	Unit of Sale NDC10 (UOS)	UoS Package	Unit of Use NDC10 (UOU)	UoU Presentation	CVX Code	CVX Long Description	CVX SI Descri
Pfizer-BioNTech	Pre-EUA for ages 6 mo to <5 yrs	Pfizer-BioNTech COVID-19 Vaccine (MAROON CAP) (Tris-sucrose formulation)	3 mcg/0.2 mL for primary series	59267-0078-4	CARTON, 10 MULTI-DOSE VIALS	59267-0078-1	VIAL, 2 mL, MULTI-DOSE VIAL	219	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation	COVID LNP-S, mL do sucros
AstraZeneca Pharmaceuticals LP	Pre-EUA	AstraZeneca COVID-19 Vaccine	5×10 ¹⁰ viral particles/0.5 mL, adult	No active NDC codes for U.S. Market				210	SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL	COVID vector ChAdC
Novavax, Inc.	Pre-EUA	Novavax COVID-19 Vaccine	5 mcg/0.5 mL, adult	No active NDC codes for U.S. Market				211	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant,	COVID Subun nanop M1 Ad mL

Unspecified US COVID-19 Vaccine CVX Code


CVX Short Description	CVX Code	CVX Long Description	Note	Vaccine Status
SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED	213	SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED	Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product is not known. CVX code 500 should be used to record Non-US vaccine where product is not known.	Inactive

The following vaccines and associated tradenames have been approved by the FDA under BLA License. They are listed separately because while they may represent the same formulations as the EUA authorized and labeled products listed above, the NDCs listed with the new BLA licensed tradenames in the FDA BLA approval or the FDA Structured Product Labels (SPL) are not currently being produced by the manufacturers while EUA product is available.

Manufacturer	FDA Authorization (BLA, EUA, Pre-EUA)	Sale Proprietary Name	Product Description	Unit of Sale NDC10 (UOS)	UoS Package	Unit of Use NDC10 (UOU)	UoU Presentation	
Pfizer-BioNTech	BLA-licensed for ages 16+	COMIRNATY	30 mcg/0.3 mL for adult 16+ (original formula)	0069-1000-02	CARTON, 195 MULTI-DOSE VIALS	0069-1000-01	VIAL, 2 mL, MULTI-DOSE VIAL	COMINARTY products are not orderable at this time. NDCs are listed per FDA Structured Product Label (SPL) document for the BLA licensed product. These codes are not included in CDC Vaccine Code Set files at this time. Pfizer has provided the following statement regarding the COMINARTY branded NDCs and labels: "Pfizer received FDA BLA license on 8/23/2021 for its COVID-19 vaccine for use in individuals 16 and older (COMIRNATY). At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 2 new NDCs (0069-1000-03, 0069-1000-02) and images of labels with the new tradename. Pfizer subsequently received approval to amend its FDA BLA License on December 16, 2021 to include its tris-sucrose formulation COVID-19 vaccine for use in individuals 16 and older
				00069-1000-03	CARTON, 25 MULTI-DOSE VIALS			
Pfizer-BioNTech	BLA-licensed for ages 16+	COMIRNATY	30 mcg/0.3 mL for adult 16+ (Same as EUA tris	0069-2025-10	CARTON, 10 MULTI-DOSE VIALS	0069-2025-01	VIAL, 2 mL, MULTI-DOSE VIAL	



Manufacturer	FDA Authorization (BLA, EUA, Pre-EUA)	Sale Proprietary Name	Product Description	Unit of Sale NDC10 (UOS)	UoS Package	Unit of Use NDC10 (UOU)	UoU Presentation	
								labels over the next few months while EUA authorized product is still available and being made available for U.S. distribution. As such, the CDC, AMA, and drug compendia may not publish these new codes until Pfizer has determined when the product will be produced with the BLA labels."
Moderna US, Inc.	BLA-licensed for ages 18+	SPIKEVAX	0.5 mL dose (same as original EUA formula)	80777-100-99	CARTON, 10 MULTI-DOSE VIALS, EACH VIAL CONTAINING 5.5 mL	NA	VIAL, 5.5 mL, MULTI-DOSE VIAL	SPIKEVAX products are not orderable at this time. NDCs are listed per FDA Structured Product Label (SPL) document for the BLA licensed product. These codes are not included in CDC Vaccine Code Set files at this time. Moderna has provided the following statement regarding the SPIKEVAX branded NDCs and labels: "Moderna received FDA BLA license on January 31, 2022, for its COVID-19 vaccine SPIKEVAX (COVID-19 Vaccine, mRNA) for use in individuals 18 and older. At that time, the FDA published a BLA package insert that included the new approved
				80777-100-98	CARTON, 10 MULTI-DOSE VIALS, EACH VIAL CONTAINING 7.5 mL	NA	VIAL, 7.5 mL, MULTI-DOSE VIAL	trade name SPIKEVAX and listed 2 new NDCs (80777-100-99, 80777-100-98). At present, Moderna does not plan to produce any product with these new NDCs and labels over the next few months while EUA authorized Moderna COVID-19 Vaccine product is still available and being made available for U.S. distribution. As such, the CDC, AMA, and drug compendia may delay publishing these new codes until Moderna has



WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO published information.

CVX Code	CVX Long Description	CVX Short Description	CVX Note	CVX Status	MX Code	MX Manufacturer	Product Tradename(s)
207	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose	COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose	EUA 12/18/2020, 2-dose vaccine. Used to record Moderna vaccines administered in the US and in non-US locations (includes tradename Spikevax)	Active	MOD	Moderna US, Inc.	Moderna COVID-19 Vaccine (non-US Spikevax)
208	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose	EUA 12/11/2020, 2-dose vaccine. Used to record Pfizer vaccines administered in the US and in non-US locations (includes tradename Comirnaty)	Active	PFR	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine (US-EUA), COMIRNATY (US-BLA), COMIRNATY (Non-US)
210	SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL	COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL	Potential EUA, 2-dose vaccine. AstraZeneca vaccine is authorized by the WHO and recognized towards immunity in the US. Non-US WHO authorized tradenames/identifiers include VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, COVISHIELD	Non-US	ASZ	AstraZeneca	AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)
212	SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL	COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL	EUA 02/27/2021, 1-dose vaccine. Used to record Janssen/J&J vaccines administered in the US and in non-US locations	Active	JSN	Janssen	Janssen (J&J) COVID-19 Vaccine
510	SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm)	COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)	WHO authorized pandemic vaccine. Recognized towards immunity in US	Non-US	SPH	Sinopharm-Biotech	Sinopharm (BIBP) COVID-19 Vaccine
511	SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac)	COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)	WHO authorized pandemic vaccine. Recognized towards immunity in US	Non-US	SNV	Sinovac	Coronavac (Sinovac) COVID-19 Vaccine
500	SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown	COVID-19 Non-US Vaccine, Product Unknown	Pandemic Non-US Covid Administration – specific CVX or product unknown	Non-US			
501	SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN)	COVID-19 IV Non-US Vaccine (QAZCOVID-IN)	Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US	Non-US			
502	SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN)	COVID-19 IV Non-US Vaccine (COVAXIN)	Pandemic Non-US Vaccine Authorized by WHO 11-3-2021, recognized toward immunity in US, https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion	Non-US	BBI	Bharat Biotech International Limited	COVAXIN (Bharat) COVID-19 Vaccine
503	SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine (CONVIVAC)	COVID-19 LAV Non-US Vaccine (CONVIVAC)	Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US	Non-US			

CVX Code	CVX Long Description	CVX Short Description	CVX Note	CVX Status	VMX Code	VMX Manufacturer	Product Tradename(s)
506	SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CanSino Biological Inc./Beijing Institute of Biotechnology)	COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)	Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US	Non-US			
507	SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences)	COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences)	Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US	Non-US			
508	SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention)	COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)	Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US	Non-US			
509	SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona)	COVID-19 PS Non-US Vaccine (EpiVacCorona)	Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US	Non-US			

COVID-19 Emergency Use Authorization Recipient and Caregiver Fact Sheets

Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers

Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for Recipients and Caregivers be provided to vaccine recipients or their caregivers.

The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is not authorized, the code will be retired.

The FDA issued Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020. Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19->

February 27, 2021. Information regarding that vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine>

The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:

- [Excel version of table](#)

CVX Code	EUA Recipient/Caregiver Fact Sheet Description	Document Barcode String	Edition Date	Edition Status	HTML URL	PDF URL	VIS GDTI document code
207	COVID-19 Moderna Vaccine EUA Recipient-Caregiver Fact Sheet	253088698300034911210601	1/31/2022	Current	https://www.cdc.gov/vaccines/covid-19/eua/modernatx.html	https://www.cdc.gov/vaccines/covid-19/eua/modernatx.pdf	0886983000349
208, 217	COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet – 12 years and older	253088698300033211210501	1/31/2022	Current	https://www.cdc.gov/vaccines/covid-19/eua/pfizer.html	https://www.cdc.gov/vaccines/covid-19/eua/pfizer.pdf	0886983000332
218	COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet – Pediatric 5 – 11 years	253088698300042411211001	1/3/2022	Current	https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children.html	https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children.pdf	0886983000424
219	COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet- Pediatric <5 yrs	253088698300048611220101	3/1/2022	Current	https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children-under-5-years.html	https://www.cdc.gov/vaccines/covid-19/eua/pfizer-children-under-5-years.pdf	0886983000486
212	COVID-19 Janssen Vaccine EUA Recipient-Caregiver Fact Sheet	253088698300036311210201	1/31/2022	Current	https://www.cdc.gov/vaccines/covid-19/eua/janssen.html	https://www.cdc.gov/vaccines/covid-19/eua/janssen.pdf	0886983000363

*Edition Date represents the date of update printed on the actual fact sheet document published by the FDA. It may not be the same as the EUA authorization date or the date embedded in the Document Barcode String.